April 25, 2019
The U.S. Food and Drug Administration approved biosimilar ETICOVO (enanercept-ykro) for the treatment of plaque psoriasis and psoriatic arthritis. It is a biosimilar to ENBREL, a biologic that first became available in 1998. [1]
Taken by injection, ETICOVO is a tumor necrosis factor blocker. It is manufactured by Samsung Bioepis Co., Ltd. [1]